WO2001083755A3 - Human anti-cd40 antibodies and methods of making and using same - Google Patents

Human anti-cd40 antibodies and methods of making and using same Download PDF

Info

Publication number
WO2001083755A3
WO2001083755A3 PCT/US2001/013672 US0113672W WO0183755A3 WO 2001083755 A3 WO2001083755 A3 WO 2001083755A3 US 0113672 W US0113672 W US 0113672W WO 0183755 A3 WO0183755 A3 WO 0183755A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
methods
making
same
human
Prior art date
Application number
PCT/US2001/013672
Other languages
French (fr)
Other versions
WO2001083755A2 (en
Inventor
Toshifumi Mikayama
Nobuaki Takahashi
Xingjie Chen
Stephen P Schoenberger
Original Assignee
Gemini Science Inc
Toshifumi Mikayama
Nobuaki Takahashi
Xingjie Chen
Stephen P Schoenberger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemini Science Inc, Toshifumi Mikayama, Nobuaki Takahashi, Xingjie Chen, Stephen P Schoenberger filed Critical Gemini Science Inc
Priority to AU2001259215A priority Critical patent/AU2001259215A1/en
Priority to US10/040,244 priority patent/US20030059427A1/en
Publication of WO2001083755A2 publication Critical patent/WO2001083755A2/en
Priority to CA2445349A priority patent/CA2445349C/en
Priority to EP07014664A priority patent/EP1914243A3/en
Priority to ES08017499.8T priority patent/ES2491265T3/en
Priority to PCT/JP2002/004292 priority patent/WO2002088186A1/en
Priority to EP08017500A priority patent/EP2011802A3/en
Priority to PT02720634T priority patent/PT1391464E/en
Priority to CA2658221A priority patent/CA2658221C/en
Priority to DK02720634T priority patent/DK1391464T3/en
Priority to EP08017499.8A priority patent/EP2009027B1/en
Priority to EP02720634A priority patent/EP1391464B1/en
Priority to DE60222658T priority patent/DE60222658T2/en
Priority to TW097138439A priority patent/TW200911837A/en
Priority to AU2002251562A priority patent/AU2002251562B2/en
Priority to CNB028130642A priority patent/CN100430419C/en
Priority to CNA2008101609045A priority patent/CN101508734A/en
Priority to TW095131602A priority patent/TWI332510B/en
Priority to ES02720634T priority patent/ES2292746T3/en
Priority to CN2008100967211A priority patent/CN101289510B/en
Priority to JP2002585483A priority patent/JP3847715B2/en
Priority to AT02720634T priority patent/ATE374214T1/en
Publication of WO2001083755A3 publication Critical patent/WO2001083755A3/en
Priority to KR1020037014090A priority patent/KR100918540B1/en
Priority to JP2006189847A priority patent/JP4025881B2/en
Priority to AU2006203620A priority patent/AU2006203620C1/en
Priority to JP2007193819A priority patent/JP4242437B2/en
Priority to JP2008275853A priority patent/JP2009079062A/en
Priority to AU2009200017A priority patent/AU2009200017A1/en
Priority to JP2009242792A priority patent/JP2010013486A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention is directed to human antibodies that bind CD40 (e.g., human CD40), methods of producing the antibodies and methods of use. Invention human CD40 antibodies include antibodies that can modulate one or more activities of CD40, such as increasing or decreasing cell proliferation. Invention human CD40 antibodies are therefore useful for increasing or decreasing a CD40 activity in order to alter CD40 activity in vivo.
PCT/US2001/013672 2000-04-28 2001-04-27 Human anti-cd40 antibodies and methods of making and using same WO2001083755A2 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
AU2001259215A AU2001259215A1 (en) 2000-04-28 2001-04-27 Human anti-cd40 antibodies and methods of making and using same
US10/040,244 US20030059427A1 (en) 2000-04-28 2001-10-26 Isolation and characterization of highly active anti-CD40 antibody
AT02720634T ATE374214T1 (en) 2001-04-27 2002-04-26 MONOCLONAL ANTI-CD-40 ANTIBODY
AU2002251562A AU2002251562B2 (en) 2001-04-27 2002-04-26 Anti-CD40 monoclonal antibody
CNB028130642A CN100430419C (en) 2001-04-27 2002-04-26 Anti-CD40 monoclonal antibody
ES08017499.8T ES2491265T3 (en) 2001-04-27 2002-04-26 Anti-CD40 monoclonal antibody
PCT/JP2002/004292 WO2002088186A1 (en) 2001-04-27 2002-04-26 Anti-cd40 monoclonal antibody
EP08017500A EP2011802A3 (en) 2001-04-27 2002-04-26 Anti-CD40 monoclonal antibody
PT02720634T PT1391464E (en) 2001-04-27 2002-04-26 Anti-cd40 monoclonal antibody
CA2658221A CA2658221C (en) 2001-04-27 2002-04-26 Anti-cd40 monoclonal antibody
DK02720634T DK1391464T3 (en) 2001-04-27 2002-04-26 Anti-CD40 monoclonal antibody
EP08017499.8A EP2009027B1 (en) 2001-04-27 2002-04-26 Anti-CD40 monoclonal antibody
EP02720634A EP1391464B1 (en) 2001-04-27 2002-04-26 Anti-cd40 monoclonal antibody
DE60222658T DE60222658T2 (en) 2001-04-27 2002-04-26 MONOCLONAL ANTI-CD-40 ANTIBODY
TW097138439A TW200911837A (en) 2001-04-27 2002-04-26 Anti-CD40 monoclonal antibody
CA2445349A CA2445349C (en) 2001-04-27 2002-04-26 Anti-cd40 monoclonal antibody
EP07014664A EP1914243A3 (en) 2001-04-27 2002-04-26 Anti-CD40 monoclonal antibody
CNA2008101609045A CN101508734A (en) 2001-04-27 2002-04-26 Anti-CD40 monoclonal antibody
TW095131602A TWI332510B (en) 2001-04-27 2002-04-26 Anti-cd40 monoclonal antibody
ES02720634T ES2292746T3 (en) 2001-04-27 2002-04-26 ANTI-CD40 MONOCLONAL ANTIBODY.
CN2008100967211A CN101289510B (en) 2001-04-27 2002-04-26 Anti-cd40 monoclonal antibody
JP2002585483A JP3847715B2 (en) 2001-04-27 2002-04-26 Anti-CD40 monoclonal antibody
KR1020037014090A KR100918540B1 (en) 2001-04-27 2003-10-27 Anti-CD40 Monoclonal Antibody
JP2006189847A JP4025881B2 (en) 2001-04-27 2006-07-10 Anti-CD40 monoclonal antibody
AU2006203620A AU2006203620C1 (en) 2001-04-27 2006-08-22 Anti-CD40 monoclonal anitbody
JP2007193819A JP4242437B2 (en) 2001-04-27 2007-07-25 Anti-CD40 monoclonal antibody
JP2008275853A JP2009079062A (en) 2001-04-27 2008-10-27 Anti-cd40 monoclonal antibody
AU2009200017A AU2009200017A1 (en) 2001-04-27 2009-01-02 Anti-CD40 monoclonal anitbody
JP2009242792A JP2010013486A (en) 2001-04-27 2009-10-21 Anti-cd40 monoclonal antibody

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20060100P 2000-04-28 2000-04-28
US60/200,601 2000-04-28

Publications (2)

Publication Number Publication Date
WO2001083755A2 WO2001083755A2 (en) 2001-11-08
WO2001083755A3 true WO2001083755A3 (en) 2002-05-23

Family

ID=22742393

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/013672 WO2001083755A2 (en) 2000-04-28 2001-04-27 Human anti-cd40 antibodies and methods of making and using same

Country Status (3)

Country Link
AU (1) AU2001259215A1 (en)
TW (1) TWI264467B (en)
WO (1) WO2001083755A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828396B2 (en) 2010-11-15 2014-09-09 Novartis Ag Silent Fc variants of anti-CD40 antibodies

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
ES2357051T3 (en) 2000-10-02 2011-04-15 Novartis Vaccines And Diagnostics, Inc. ANTI-CD40 HUMAN ANTIBODIES.
US20020102259A1 (en) * 2000-11-03 2002-08-01 Jun Tan Methods and compositions for stimulating CD 45 and thereby suppressing microglial activation associated with Alzheimer's disease
CA2658221C (en) 2001-04-27 2012-11-27 Kyowa Hakko Kirin Co., Ltd. Anti-cd40 monoclonal antibody
WO2003028809A1 (en) * 2001-10-02 2003-04-10 Chiron Corporation Methods of therapy for b-cell malignancies
WO2003029296A1 (en) * 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
AR039067A1 (en) * 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
EP1455812A4 (en) * 2001-11-26 2006-03-22 Chiron Corp Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
CA2544368C (en) * 2003-11-04 2014-04-01 Chiron Corporation Methods of therapy for b cell-related cancers
WO2005044855A2 (en) * 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
PT1682178E (en) * 2003-11-04 2010-10-21 Novartis Vaccines & Diagnostic Methods of therapy for cancers expressing the cd40 antigen
PT1682177E (en) * 2003-11-04 2010-11-29 Xoma Technology Lt Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
EP1761311A2 (en) * 2004-04-27 2007-03-14 Novartis Vaccines and Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
KR20080073725A (en) 2005-11-01 2008-08-11 노파르티스 아게 Uses of anti-cd40 antibodies
WO2007124299A2 (en) 2006-04-21 2007-11-01 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
MX2010005080A (en) 2007-11-07 2010-07-28 Genentech Inc Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies.
WO2010104747A2 (en) 2009-03-10 2010-09-16 Baylor Research Institute Antigen presenting cell targeted vaccines
ES2650267T3 (en) * 2008-12-05 2018-01-17 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
MX2011009439A (en) 2009-03-10 2013-06-18 Baylor Res Inst Antigen presenting cell targeted vaccines.
MX2011009438A (en) 2009-03-10 2012-04-02 Baylor Res Inst Anti-cd40 antibodies and uses thereof.
CN102459639A (en) 2009-04-18 2012-05-16 健泰科生物技术公司 Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
US20120301465A1 (en) 2011-03-25 2012-11-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods to immunize against hepatitis c virus
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
GB201322583D0 (en) * 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
US10286058B2 (en) 2014-01-13 2019-05-14 Baylor Research Institute Vaccines against HPV and HPV-related diseases
DK3180087T3 (en) 2014-08-12 2019-05-13 Alligator Bioscience Ab COMBINATION THERAPIES WITH ANTI CD40 ANTIBODIES
MA41459A (en) 2015-02-03 2017-12-12 Als Therapy Development Inst ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS
BR112018006360A2 (en) 2015-09-30 2018-10-09 Janssen Biotech Inc agonistic antibodies that specifically bind to human cd40 and methods of use
MA45488A (en) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh CELL CULTURE PROCESSES, KITS AND APPARATUS
KR20180069070A (en) 2015-11-03 2018-06-22 얀센 바이오테크 인코포레이티드 Antibodies that specifically bind to TIM-3 and uses thereof
KR102379464B1 (en) 2016-06-20 2022-03-29 키맵 리미티드 anti-PD-L1 antibody
KR102554331B1 (en) 2016-08-12 2023-07-10 얀센 바이오테크 인코포레이티드 Fc engineered anti-TNFR superfamily member antibodies with enhanced agonistic activity and methods of use thereof
CA3033661A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
NZ758485A (en) 2017-04-27 2024-02-23 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
WO2018217918A2 (en) 2017-05-24 2018-11-29 Als Therapy Development Institute Therapeutic anti-cd40 ligand antibodies
KR102198998B1 (en) 2017-06-01 2021-01-07 서울대학교 산학협력단 Novel anti-cd40 antibodies and uses thereof
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
KR20210069639A (en) 2018-08-30 2021-06-11 에이치씨더블유 바이올로직스, 인크. Single-chain chimeric polypeptides and uses thereof
CN113015744A (en) 2018-08-30 2021-06-22 Hcw生物科技公司 Single-chain chimeric polypeptide and multi-chain chimeric polypeptide and application thereof
AU2019328290A1 (en) 2018-08-30 2021-02-25 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CN109678959B (en) * 2019-02-22 2020-12-08 北京免疫方舟医药科技有限公司 anti-CD 40 antibodies and uses thereof
CA3143035A1 (en) 2019-06-21 2020-12-24 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996033735A1 (en) * 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) * 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5801227A (en) * 1993-10-01 1998-09-01 Fanslow, Iii; William C. Antibodies to CD40
EP0945465A1 (en) * 1992-07-09 1999-09-29 Chiron Corporation Antagonistic monoclonal antibodies to human CD40
WO2000000156A2 (en) * 1998-06-26 2000-01-06 Trustees Of Dartmouth College Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0945465A1 (en) * 1992-07-09 1999-09-29 Chiron Corporation Antagonistic monoclonal antibodies to human CD40
US5801227A (en) * 1993-10-01 1998-09-01 Fanslow, Iii; William C. Antibodies to CD40
WO1996033735A1 (en) * 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) * 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO2000000156A2 (en) * 1998-06-26 2000-01-06 Trustees Of Dartmouth College Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. LAGERKVIST ET AL.: "Single, antigen-specific B cells used to generate Fab fragments using CD40-mediated amplification or direct PCR cloning.", BIOTECHNIQUES, vol. 18, no. 5, May 1995 (1995-05-01), Natick, USA, pages 862 - 869, XP000572659 *
P. KARLSSON ET AL.: "Selection of human single chain antibodies against CD40.", IMMUNOLOGY LETTERS, vol. 73, no. 2-3, September 2000 (2000-09-01), Amsterdam, The Netherlands, pages 161, XP002185388 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8828396B2 (en) 2010-11-15 2014-09-09 Novartis Ag Silent Fc variants of anti-CD40 antibodies

Also Published As

Publication number Publication date
TWI264467B (en) 2006-10-21
WO2001083755A2 (en) 2001-11-08
AU2001259215A1 (en) 2001-11-12

Similar Documents

Publication Publication Date Title
WO2001083755A3 (en) Human anti-cd40 antibodies and methods of making and using same
WO2002028905A3 (en) Human anti-cd40 antibodies
WO2001078702A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
AU2002366083A1 (en) Matrix for the production of tissue engineered ligaments, tendons and other tissue
WO2003032916A3 (en) Organosulfur inhibitors of tyrosine phosphatases
AU2002320317A1 (en) Novel mesogens and methods for their synthesis and use
AU2002356861A1 (en) Fibrin membrane and methods for its preparation- application to artificial skin
WO2004007682A3 (en) Methods and compositions for modulating t helper (th) cell development and function
WO2001078703A3 (en) Methods and compositions for modulating alpha adrenergic receptor activity
WO2004009036A3 (en) Compounds compositions and methods
AU2001247600A1 (en) Methods of modulating hair growth
WO2004032840A3 (en) Compounds, compositions, and methods
WO2004034972A3 (en) Compounds, compositions, and methods
WO2004113528A3 (en) Isoforms of elf-5a: senescence-induced elf5a; wounding-induced elf-5a; growth elf-5a; and dhs
WO2003006614A3 (en) UBE2s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2004003152A3 (en) Sos1 inhibitors
MY127675A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
AU4779599A (en) Methods of inhibiting (helicobacter pylori)
WO2004024086A3 (en) Compounds, compositions and methods
WO2004032879A3 (en) Compounds, compositions, and methods
AU2003205751A8 (en) Plant growth modulation by drl1 and other proteins of the elongator complex
AU2002246585A1 (en) Plant promoters, and methods of use
AU2003266960A1 (en) Composition for the treatment of pain, especially for the treatment of articular pain
AU2001277737A1 (en) Novel substance having physiological activity, process for producing the same, and use
AU2003202255A1 (en) Compositions for treatment of central nervous system neoplasms, and methods of making and using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP